Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company was established in 2000 and is based in Stockholm, Sweden.
Oncopeptides has developed melflufen (Ygalo®), the first peptidase potentiated cytotoxic therapy intended for use in the treatment of multiple myeloma. The first clinical indication is late-stage relapsed and refractory multiple myeloma.
Melflufen is unique in its ability to kill cancer cells up to fifty-times more effectively than existing cytotoxic treatments, without a similar increase in effect on the patient’s bone marrow, as demonstrated in clinical and pre-clinical studies.
Comparion of the clinical data between melflufen and the current standard of care in multiple myeloma indicates that treatment with melflufen increases overall survival, progression free survival and improves the percentage of patients with significant tumour burden reduction – as well as being better tolerated by patients.
Melflufen has undergone the US Food and Drug Administration’s Special Protocol Assessment process for a pivotal Phase 3 study of patients with multiple myeloma. The study started in June 2017 and will compare melflufen directly against the current standard of care. A successful conclusion to this study will likely lead to regulatory approval in the US and Europe.
Each year, approximately three in every 10,000 people are diagnosed with multiple myeloma*. While multiple myeloma can affect people of any age, the average age of diagnosis is 70 years of age. As there is no cure for multiple myeloma, a key focus of treatment is extending and improving the quality of life for patients, particularly in the final stages of the disease.
In 2016, global sales of the current standard of care for comparable late-stage multiple myeloma patients represented approximately USD 1.3 billion. This market is expected to grow to a value of USD 2.3 billion* by 2019 driven mainly by an ageing population and improved treatments.
* National Cancer Institute, SEER Cancer Statistics Review 1975-2013 (2016) for patients in USA and GlobalData (2015).
* GlobalData (2016). Sales data for lenalidomide and pomalidomide are based on an average analysts’ estimate and refers to global sales